Astria Therapeutics, Inc. (NASDAQ:ATXS) Given Average Recommendation of “Buy” by Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been assigned a consensus recommendation of “Buy” from the eight research firms that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $30.00.

Several research firms have issued reports on ATXS. Wedbush reaffirmed an “outperform” rating and issued a $28.00 price target (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $47.00 price target on shares of Astria Therapeutics in a report on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Friday, June 13th.

Institutional Trading of Astria Therapeutics

Several large investors have recently added to or reduced their stakes in ATXS. Fcpm Iii Services B.V. acquired a new stake in Astria Therapeutics during the 4th quarter valued at $25,680,000. ADAR1 Capital Management LLC grew its holdings in shares of Astria Therapeutics by 605.3% during the 1st quarter. ADAR1 Capital Management LLC now owns 641,690 shares of the biotechnology company’s stock valued at $3,427,000 after acquiring an additional 550,706 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Astria Therapeutics by 4.5% during the 4th quarter. Vestal Point Capital LP now owns 4,180,000 shares of the biotechnology company’s stock valued at $37,369,000 after acquiring an additional 180,000 shares in the last quarter. Nuveen LLC purchased a new position in shares of Astria Therapeutics during the 1st quarter valued at $553,000. Finally, Jane Street Group LLC grew its holdings in shares of Astria Therapeutics by 317.3% during the 1st quarter. Jane Street Group LLC now owns 108,898 shares of the biotechnology company’s stock valued at $582,000 after acquiring an additional 82,805 shares in the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS opened at $5.81 on Monday. Astria Therapeutics has a 12 month low of $3.56 and a 12 month high of $12.92. The stock has a market cap of $327.86 million, a price-to-earnings ratio of -3.11 and a beta of 0.41. The stock’s 50 day moving average price is $5.02 and its 200 day moving average price is $6.09.

Astria Therapeutics (NASDAQ:ATXS) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, sell-side analysts expect that Astria Therapeutics will post -1.65 EPS for the current year.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.